In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Outset Medical (OM – Research Report), with a price target of $9.00. The company’s shares closed last Friday at $4.25.
Jennings covers the Healthcare sector, focusing on stocks such as Boston Scientific, Abbott Labs, and Alphatec Holdings. According to TipRanks, Jennings has an average return of 0.5% and a 47.08% success rate on recommended stocks.
Currently, the analyst consensus on Outset Medical is a Moderate Buy with an average price target of $10.80.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $30.55 and a one-year low of $2.90. Currently, Outset Medical has an average volume of 1.12M.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Outset Medical (OM) Company Description:
Outset Medical Inc is a medical technology company. The company has developed a machine, Tablo, which reduces the cost and complexity of dialysis.
Read More on OM:
- Netflix downgraded, Applied Materials upgraded: Wall Street’s top analyst calls
- Outset Medical downgraded to Underperform from Buy at BofA
- Outset Medical price target lowered to $17 from $29 at RBC Capital
- Outset Medical price target lowered to $9 from $32 at TD Cowen
- Outset Medical price target lowered to $6 from $26 at Stifel
